CEO SUMMARY: Now that the FDA has cleared a digital pathology for use in primary diagnosis, interest in DP is building. Inspirata purchased Omnyx and its assets because the Omnyx Dynamyx digital pathology software has strong features that could be integrated into Inspirata’s digital pathology solution. In this interview with THE DARK REPORT, Inspirata CEO
IN RECENT WEEKS, pathology laboratory clients of the Omnyx digital pathology system learned that the joint venture is ending. Company officials tell these customers that their digital pathology systems will continue to receive service.
Omnyx was formed in 2008 as a joint venture between GE Healthcare and the University of Pittsburgh Medical Center (UPMC). Its goal
CEO SUMMARY: There’s a new competitor in the digital pathology marketplace with ambitious plans to deliver a fully-integrated pathologist workflow solution. Inspirata, Inc., of Tampa, Florida, made its debut in March at an international pathology conference. In this exclusive interview, Inspirata Chairman and CEO Satish K. Sanan explains his company’s strategic vision for digital pathology, along with the details of how Inspirata intends to overcome digital pathology’s return-on-investment challenge.
Last month, it was announced that Solstas Lab Partners of Greensboro, North Carolina, had agreed to be sold to Quest Diagnostics Incorporated. The sales price is $570 million and financial analysts on Wall Street estimate that the annual revenue at Solstas Lab Partners is about $350 million. This would indicate that Quest Diagnostics paid a
Currently there are 119 operational health information exchanges (HIEs) in the United States. This number is 58% greater than the 75 HIEs that were operational in 2010. These numbers were reported in Health Affairs. The study was authored by researchers at the University of Michigan. They also determined that 30% of the nation’s hospitals and
There is progress on the integration of digital pathology systems and proprietary algorithms designed to help pathologists make diagnoses. This month, Visiopharm and Omnyx LLC, announced a joint venture. On its own, in Europe last year, Visiopharm earned a CE mark for its “in vitro diagnostic (IVD) software module for the breast cancer marker HER2.”
CEO SUMMARY: GE Healthcare and Omnyx chose Canada to be the location of their new Global Pathology Innovation Centre of Excellence (PICOE). PICOE’s mission is to demonstrate that digital pathology can improve patient outcomes in a cost-effective manner. GE and Omnyx will use PICOE as a proving ground for the value of digital pathology, while
In Nigeria, the kidnap of a professor of pathology at the University of Uyno last month caused work stoppages by academic union members in protest of the government’s failure to protect medical faculty from the recent rash of kidnappings. Pathologist Dr. Memfin Ekpo was abducted by gunmen during a church service on January 16. His
CEO SUMMARY: What makes 2010 a watershed year for the laboratory testing industry is enactment of the 2,700-page Patient Protection and Affordable Care Act (PPACA). Even if parts of this bill are repealed, the remaining parts of the massive legislation will trigger major changes to the healthcare system as it operates today. Other stories in
CEO SUMMARY: Not in recent memory has a laboratory information system (LIS) product been pulled from the market. That is why the announcement by GE Healthcare that it would no longer service or support its Centricity Ultra Laboratory product after July 23, 2013, has caused a stir within the healthcare informatics industry. In the United